10亿美元!礼来收购非阿片类疼痛疗法初创公司SiteOne

医药魔方
28 May

5月27日,礼来和SiteOne Therapeutics宣布达成确定性协议,礼来将收购SiteOne。SiteOne是一家致力于开发钠通道小分子抑制剂以治疗疼痛和其他神经元过度兴奋性疾病的初创生物技术公司。根据协议条款,SiteOne股东将获得高达10亿美元的现金,包括前期付款以及在实现某些监管和商业里程碑后支付的后续款项。此次收购是在SiteOne的大轮融资之后进行的。2024年12月,这家...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10